Participant flow

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer · Source last updated 2026-05-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).

   id

   FG000

   title

   UGN-102

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         171

      type

      Ongoing in the Study

   2. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Noncompliance

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Physician Decision

   7. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Other Reason

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         240

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         43

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         197

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice